What are the clinical implications of new onset or worsening anxiety during the first two weeks of SSRI treatment for depression?
- 6 December 2011
- journal article
- research article
- Published by Hindawi Limited in Depression and Anxiety
- Vol. 29 (2) , 94-101
Abstract
Objective To evaluate the prevalence of new onset or worsening of anxiety symptoms, as well as their clinical implications, during the first 2 weeks of Selective Serotonin Reuptake Inhibitor (SSRI) pharmacotherapy for depression. Method Adult outpatients with nonpsychotic major depressive disorder were enrolled in an 8‐week acute phase SSRI treatment trial at 15 clinical sites across the United States. Worsening anxiety was defined as a greater than 2‐point increase on the Beck Anxiety Inventory (BAI) between baseline and Week 2. New onset of anxiety symptoms was ascribed when the BAI baseline rating was 0 and the Week 2 value was greater or equal to 2 points on the BAI. Results Overall, after 2 weeks of treatment, 48.8% (98 of 201 participants) reported improvement in anxiety symptoms, 36.3% (73 of 201) reported minimal symptom change, and 14.9% (30 of 201) reported worsening of anxiety symptoms. No association was found between change in anxiety symptoms within the first 2 weeks and change in depressive symptoms or remission at the end of 8 weeks of treatment. For participants with clinically meaningful anxiety symptoms at baseline, however, worsening of anxiety during the first 2 weeks of treatment was associated with worsening depressive symptoms by 8 weeks (P = .054). Conclusions The trajectory of anxiety symptom change early in SSRI treatment is an important indicator of eventual outcome for outpatients with major depression and baseline anxiety symptoms. Depression and Anxiety 0:1–8, 2011.Keywords
This publication has 45 references indexed in Scilit:
- Early Adverse Events and Attrition in Selective Serotonin Reuptake Inhibitor TreatmentJournal of Clinical Psychopharmacology, 2010
- Sex differences in depression symptoms in treatment-seeking adults: confirmatory analyses from the Sequenced Treatment Alternatives to Relieve Depression studyComprehensive Psychiatry, 2008
- Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: A meta-analysis of individual patient data from 10 double-blind, randomized clinical trialsJournal of Psychiatric Research, 2008
- Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinicNature Neuroscience, 2007
- Measurement-based care for refractory depression: A clinical decision support model for clinical research and practiceDrug and Alcohol Dependence, 2007
- Clinical correlates of anxious depression among elderly patients with depressionJournal of Affective Disorders, 2006
- Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*DPsychological Medicine, 2004
- The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluationPsychological Medicine, 2004
- Antidepressant Drug Interactions and the Cytochrome P450 SystemClinical Pharmacokinetics, 1995
- A RATING SCALE FOR DEPRESSIONJournal of Neurology, Neurosurgery & Psychiatry, 1960